DMAA Targeted In N.Y. Ban Effort, USP Labs Settles
This article was originally published in The Tan Sheet
A New York lawmaker moves to ban DMAA sales in the state, and USP Labs sets aside $2 million to settle class action suit over the product. FDA continues to work with firms that received related warning letters.
You may also be interested in...
FDA’s warning letters to 10 marketers of DMAA-containing products might have a silver lining for the supplement industry as they suggest the agency may be flexible on its controversial interpretation of some provisions in the new dietary ingredient notification requirement.
Complaints against GNC Holdings Inc., manufacturer Cellucor Sports Nutrition and Woodbolt Distribution and against USPLabs rely on DOD’s decision to ban sales of the product at military exchanges and moves by Canadian regulators to support their arguments.
DoD suspends DMAA sales at military stores after regulators in Canada and New Zealand restricted access and as some U.S. firms change how they market and label the ingredient. These moves and the potential for an FDA review could lead to enforcement against DMAA similar to the 2004 ban against ephedra’s use in supplements.